ReviewCancers2026
Multi-Omics and Liquid Biopsy Integration for Precision Stratification of Breast Cancer.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a biologically heterogeneous disease that requires accurate diagnosis, risk stratification, treatment selection and longitudinal assessment. Conventional imaging and tissue biopsy remain the mainstays of clinical management. However, tissue sampling represents a specific anatomical site and time point, and may not reflect the molecular heterogeneity or evolution of disease. Liquid biopsy offers a minimally invasive complementary approach, analyzing circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and extracellular vesicles. Applications include molecular characterization, treatment-response assessment, resistance detection and minimal residual disease (MRD) evaluation, which are under investigation or in clinical use. Gene-expression profiles, mutational alterations and epigenetic marks can generate molecular signatures that offer further support for tumor classification and risk stratification, and have demonstrated clinical value in specific breast cancer populations. Advances in next-generation sequencing, digital PCR, proteomic analysis, and artificial intelligence have expanded the analytical capacity for detection and interpretation of circulating and tissue-derived biomarkers. However, biological heterogeneity, low abundance of circulating biomarkers, pre-analytical and analytical variability, standardization of assays and limited prospective evidence for some applications are still major barriers to clinical translation. In this review, we discuss the biological basis, detection technologies, clinical applications and limitations of liquid biopsies and molecular signatures in breast cancer, highlighting multi-omics integration and computational approaches. It distinguishes between promising analytical biomarkers and clinically validated applications and highlights the evidence and methodological needs for wider implementation in precision breast cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.